The potential application of sorbents in peritoneal dialysis

Contributions to Nephrology

Volumn 150, Issue , 2006, Pages 336-343

  Winchester, James F ^a   Amerling, Richard ^a   Harbord, Nicolas ^a   Capponi, Vincent ^b   Ronco, Claudio ^c  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b MedaSorb Technologies Inc   (United States)

^c SAN BORTOLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DETOXIFICATION; HUMAN; METHODOLOGY; PERITONEAL DIALYSIS; REVIEW;

HUMANS; PERITONEAL DIALYSIS; SORPTION DETOXIFICATION;

EID: 33745261770     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000093628     Document Type: Review

References (38)

1. Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, Mujais S, Mexican Nephrology Collaborative Study Group: Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002;13:1307-1320.
2. Amerling R, DeSimone L, Inciong-Reyes R, Pangilinan A, Folden T, Ronco C, Gotch FA, Levin N: Clinical experience with continuous flow and flow-through peritoneal dialysis. Semin Dial 2001;14:388-390.
3. Amerling R, Glezerman I, Savransky E, Dubrow A, Ronco C: Continuous flow peritoneal dialysis: current perspectives. Contrib Nephrol 2003;140:294-304.
4. Dell'Aquila R, Rodighiero MP, Bordoni V, D'Intini V, Ronco C: APD prescription: achieving the adequacy goals. Semin Dial 2002;15:397-402.
5. Diaz-Buxo JA: Streaming, mixing, and recirculation: role of the peritoneal access in continuous flow peritoneal dialysis (clinical considerations). Adv Perit Dial 2002;18:87-90.
6. Ash SR, Sutton JM, Mankus RA, Rossman J, de Ridder V, Nassvi MS, Ross J: Clinical trials of the T-fluted (Ash Advantage) peritoneal dialysis catheter. Adv Ren Replace Ther 2002;9:133-143.
7. Vanholder R, De Smet R, Glorieux G, et al, for the European Uremic Toxin Work Group: Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003;63:1934-1943.
8. Bostom AG, Shemin D, Lapane KL, et al: Hyperhomocysteinemia and traditional cardiovascular risk factors in end-stage renal disease patients on dialysis: a case-control study. Atherosclerosis 1995;114:93-103.
9. Henle T, Deppisch RM, Beck W, et al: Advanced glycation end-products during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds. Nephrol Dial Transplant 1999;14:1968-1975.
10. Farrell PC, Gotch FA, Peters JH, et al: Binding of hippurate in normal plasma and in uremic plasma pre- and postdialysis. Nephron 1978;20:40-46.
11. Babb AL, Ahmad S, Bergström J, Scribner BH: The middle molecule hypothesis in perspective. Am J Kidney Dis 1981;1:46-50.
12. Clark WR, Gao D: Low-molecular weight proteins in end-stage renal disease: potential toxicity and dialytic removal mechanisms. J Am Soc Nephrol 2002;13:S41-S47.
13. Gejyo F, Yamada T, Odani S, Nakagawa Y, Arakawa M, Kunitumo T, Kataoka H, Suzuki M, Hirasawa Y, Shirahama T, Cohen A, Schmid K: A new form of amyloid protein associated with chronic hemodialysis was identified as beta2-microglobulin. Biochem Biophys Res Commun 1985;129:701-706.
14. Makita Z, Bucala R, Rayfield EJ, Friedman EA, Kaufman AM, Korbet SM, Barth RH, Winston JA, Fuh H, Manogue KR, Cerami A, Vlassara H: Reactive glycosylation endproducts in diabetic uremia and treatment of renal failure. Lancet 1994;343:1519-1522.
15. Bohlender JM, Franke S, Stein G, Wolf G: Advanced glycation end products and the kidney. Am J Physiol Renal Physiol 2005;289:F645-F659.
16. Ishimitsu T, Nishikimi T, Saito Y, et al: Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. J Clin Invest 1994;94:2158-2161.
17. Sharma K, Considine RV, Michael B, et al: Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients. Kidney Int 1997;51:1980-1985.
18. Matsubara K, Kiyomoto H, Moriwaki K, Hara T, Kondo N, Shokoji T, Hitomi H, Aki Y, Aono M, Nishiyama A, Ohmori K, Kohno M: Leptin kinetics during peritoneal dialysis in acutely uraemic rats. Nephrology 2004;9:256-261.
19. Deppisch RM, Beck W, Goehl H, Ritz E: Complement components as uremic toxins and their potential role as mediators of microinflammation. Kidney Int 2001;78(suppl):S308-S314.
20. Pereira BJ, Shapiro L, King AJ, et al: Plasma levels of IL-1p, TNF, and their specific inhibitors in undialyzed chronic renal failure, CAPD, and hemodialyzed patients. Kidney Int 1994;45:890-896.
21. Kaizu Y, Kimura M, Yoneyama T, et al: Interleukin-6 may mediate malnutrition in chronic hemodialysis patients. Am J Kidney Dis 1998;31:93-100.
22. Agalou S, Ahmed N, Thornalley PJ, Dawnay A: Advanced glycation end product free adducts are cleared by dialysis. Ann NY Acad Sci 2005;1043:734-739.
23. Winchester JF: Hemoperfusion; in Horl W, Koch KM, Lindsay RM, Ronco C, Winchester JF (Editor in Chief) (eds): Replacement of Renal Function by Dialysis, ed 5. Dordrecht, Kluwer Academic Publishers, 2004, pp 725-738.
24. Mikhalovsky SV: The detoxication with bioselective carbon sorbents. Biomater Artif Cells Artif Organs 1989;17:157-160.
25. Winchester JF, Ratcliffe JG, Carlyle E, Kennedy AC: Solute, amino acid, and hormone changes with coated charcoal hemoperfusion in uremia. Kidney Int 1978;14:74-81.
26. Kokot F, Pietrek J, Seredynski M: Influence of haemoperfusion on plasma levels of hormones and B-methyldigoxin. Proc Eur Dial Transplant Assoc 1978;15:604.
27. Winchester JF, Silberzweig J, Ronco C, Kuntsevich V, Levine D, Parker T, Kellum JA, Salsberg JA, Quartararo P, Levin NW: Sorbents in acute renal failure and end stage renal disease: middle molecule and cytokine removal. Blood Purif 2004;22:73-77.
28. Gejyo F, Kawaguchi Y, Hara S, Nakazawa R, Azuma N, Ogawa H, Koda Y, Suzuki M, Kaneda H, Kishimoto H, Oda M, Ei K, Miyazaki R, Maruyama H, Arakawa M, Hara M: Arresting dialysis-related amyloidosis: a prospective multicenter controlled trial of direct hemoperfusion with a beta2-microglobulin adsorption column. Artif Organs 2004;28:371-380.
29. Bellomo R, Tetta C, Ronco C: Coupled plasma filtration adsorption. Intensive Care Med 2003;29:1222-1228.
30. Davankov V, Pavlova L, Tsyurupa M, Brady J, Balsamo M, Yousha E: Polymeric adsorbent for removing toxic proteins from blood of patients with kidney failure. J Chromatogr Biomed Sci Appl 2000;739:73-80.
31. Ash SR, Baker K, Blake DE, Carr DJ, Echard TG, Sweeney KD, Handt AE, Wimberly AL: Clinical trials of the BioLogic-HD. Automated single access, sorbent-based dialysis. ASAIO Trans 1987;33:524-531.
32. Patzer JF 2nd, Yao SJ, Wolfson SK Jr: Zeolitic ammonium ion exchange for portable hemodialysis dialysate regeneration. ASAIO J 1995;41:221-226.
33. Gordon A, Maxwell MH, Lewin AJ: Sorbent regeneration of peritoneal dialysate: an approach to ambulatory dialysis. J Dial 1976-77;1:145-164.
34. Ash SR: The allient dialysis system. Semin Dial 2004;17:164-166.
35. Ishikawa N, Miyata T, Ueda Y, Inagi R, Izuhara Y, Yuzawa H, Onogi H, Nishina M, Nangaku M, Van Ypersele De Strihou C, Kurokawa K: Affinity adsorption of glucose degradation products improves the biocompatibility of conventional peritoneal dialysis fluid. Kidney Int 2003;63:331-339.
36. Lang HL, Nolph KD, McGary TJ: Enhancement of clearances by activated charcoal in an in vitro model of peritoneal dialysis. Clin Exp Dial Apheresis 1982;6:85-95.
37. Blumenkrantz MJ, Lewin AJ, Gordon A, Roberts M, Pecker EA, Coburn JW, Maxwell MH: Development of a sorbent peritoneal dialysate regeneration system - a progress report. Proc Eur Dial Transplant Assoc 1978;15:213-219.
38. Roberts M, Ash SR, Lee DB: Innovative peritoneal dialysis: flow-thru and dialysate regeneration. ASAIO J 1999;45:372-378.